International Journal of Endocrinology / 2017 / Article / Tab 3

Research Article

Therapeutic Outcomes of Patients with Multifocal Papillary Thyroid Microcarcinomas and Larger Tumors

Table 3

Clinical features of multifocal papillary thyroid cancer in nonremission or remission.

Clinical characteristicsAll patientsNonremissionRemission value

Patient number626 (100.0)131 (20.9)495 (79.1)
Gender, female499 (79.7)84 (64.1)415 (83.8)<0.001
Age at diagnosis (year)46.5 ± 13.547.8 ± 17.146.1 ± 12.40.214
Mean tumor size (cm)2.1 ± 1.42.6 ± 1.72.0 ± 1.3<0.001
1-month postoperative serum Tg level (ng/mL)184.2 ± 1551.1770.2 ± 3286.725.3 ± 102.8<0.001
Operative method
 Total thyroidectomy595 (95.0)127 (96.9)468 (94.5)0.260
 Less than total thyroidectomy31 (5.0)4 (3.1)27 (5.5)
TNM stage
 Stage I390 (62.3)53 (40.5)337 (68.1)<0.001
 Stage II58 (9.3)15 (11.5)43 (8.7)0.332
 Stage III67 (10.7)14 (10.7)53 (10.7)0.995
 Stage IV111 (17.7)49 (37.4)62 (12.5)<0.001
Follow-up period (year)7.1 ± 5.37.4 ± 5.57.0 ± 5.30.478
Postoperative 131I accumulative dose (mCi)153.7 ± 222.2384.2 ± 366.492.8 ± 95.5<0.001
Radiation therapy28 (4.5)27 (20.6)1 (0.2)<0.001
2nd primary cancer49 (7.8)15 (11.5)34 (6.9)0.083
Diabetes mellitus61 (9.7)13 (9.9)48 (9.7)0.938
Overall mortality49 (7.8)29 (22.1)20 (4.0)<0.001
Cancer mortality25 (4.0)24 (18.3)1 (0.2)<0.001
Disease-free221 (35.3)16 (12.2)205 (41.4)<0.001

Number (%); mean ± SD.

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.